Literature DB >> 33555614

Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements.

Michael Ming Cheuk Wong1, Albert Kar Kin Chung1, Timothy Ming Hong Yeung2, David Tai Wai Wong2, Che Kin Lee3, Eric Lai4, Gloria Fong Yeung Chan2, Gregory Kai Lok Mak2, Jessica Oi Yin Wong3, Roger Man Kin Ng5, Ki Yan Mak2,6.   

Abstract

AIMS: There is increasing evidence showing the importance of long-acting injectable antipsychotics in the management of schizophrenia, especially in terms of improving patient medication compliance. A panel of experienced clinicians in Hong Kong mapped out a set of consensus statements with an aim to facilitate the understanding and use of long-acting injectable antipsychotics among local physicians.
METHODS: Eight discussion areas regarding long-acting injectable antipsychotics were selected by the chairman of the consensus group. A series of meetings were held for the panelists to discuss the published literature and their clinical experience, followed by the drafting of consensus statements. At the final meeting, each consensus statement was voted on anonymously by all members based on its practicability of recommendation in Hong Kong.
RESULTS: A total of 12 consensus statements on the rational use of long-acting injectable antipsychotics were established and accepted by the consensus group.
CONCLUSION: The consensus statements aim to provide practical guidance for Hong Kong physicians on the use of long-acting injectable antipsychotics in schizophrenia patients. These statements may also serve as a reference for doctors in other parts of the Asia-Pacific region.
© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  consensus statements; guidance; long-acting injectable antipsychotics; schizophrenia

Mesh:

Substances:

Year:  2021        PMID: 33555614      PMCID: PMC7869935          DOI: 10.1111/cns.13374

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  52 in total

1.  Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

Authors:  Pierre Chue; Marielle Eerdekens; Ilse Augustyns; Bernard Lachaux; Peter Molcan; Lars Eriksson; H Pretorius; Anthony S David
Journal:  Eur Neuropsychopharmacol       Date:  2005-01       Impact factor: 4.600

2.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Authors:  Jari Tiihonen; Jari Haukka; Mark Taylor; Peter M Haddad; Maxine X Patel; Pasi Korhonen
Journal:  Am J Psychiatry       Date:  2011-03-01       Impact factor: 18.112

3.  Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.

Authors:  Patricia Gassó; Sergi Mas; Oriol Molina; Miquel Bernardo; Amalia Lafuente; Eduard Parellada
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-08-22       Impact factor: 5.067

4.  Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

Authors:  Matthias Jaeger; Wulf Rossler
Journal:  Psychiatry Res       Date:  2009-12-11       Impact factor: 3.222

5.  Medication adherence of individuals with a first episode of psychosis.

Authors:  E L Coldham; J Addington; D Addington
Journal:  Acta Psychiatr Scand       Date:  2002-10       Impact factor: 6.392

6.  Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.

Authors:  Borah Kim; Sang-Hyuk Lee; Tae Kyou Choi; ShinYoung Suh; Yong Woo Kim; EunHee Lee; Ki Hwan Yook
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-03-25       Impact factor: 5.067

Review 7.  Early intervention in psychosis. The critical period hypothesis.

Authors:  M Birchwood; P Todd; C Jackson
Journal:  Br J Psychiatry Suppl       Date:  1998

8.  Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

9.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

10.  Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Authors:  Hyun-Ghang Jeong; Moon-Soo Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.